HiFiBio submits IND for SARS-CoV-2 treatment

By The Science Advisory Board staff writers

August 26, 2020 -- HiFiBio Therapeutics has submitted an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for novel SARS-CoV-2 neutralizing antibodies for the treatment of COVID-19 patients.

The differentiated antibody, Hfb30132A, has been developed with the company's single-cell profiling platform and evaluated in multiple preclinical studies. The anti-SARS-CoV-2 recombinant antibody is designed with specific sequences identified from B cells of a COVID-19 convalescent patient.

Hfb30132A binds to the viral spike protein and neutralizes several mutated strains of the virus, including the mutant D614G. The company expects the product to be used as a monotherapy for treatment and prevention against SARS-CoV-2.

Within the next six months HiFiBio expects to begin a phase I single-intravenous administration ascending dose clinical trial will assess the safety, tolerability, and pharmacokinetics of the products in healthy volunteers.

HiFiBio partners with CoVIC for SARS-CoV-2 antibody therapies
HiFiBio Therapeutics and the Coronavirus Immunotherapy Consortium (CoVIC) will collaborate to develop SARS-CoV-2-neutralizing antibodies with potential...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter